Researchers determined that a mere 1.5 percent of high-risk patients
were prescribed naloxone, which can reverse an overdose, according
to the study published in JAMA Network Open.
"We expected to see a low number, but what we found was very
surprising," said study coauthor Dr. Mai Tuyet Pho, an assistant
professor in the section of Infectious Diseases and Global Health at
the University of Chicago Medical Center. "Naloxone is very, very
much underutilized in the healthcare setting. This presents a huge
opportunity for healthcare providers to talk to their patients,
particularly those at risk for overdose, about naloxone and how to
use it."
To take a closer look at naloxone prescriptions, Pho and her team
turned to a national database of private insurance claims, Truven
Health MarketScan. They analyzed data collected between October 1,
2015 and December 31, 2016.
Out of nearly 33.5 million individuals in the database, researchers
identified 138,108 U.S. patients aged 15 and older with claims
related to opioid misuse or dependence, opioid related overdose, or
both. Among those patients, just 2,135, or 1.5 percent, received
prescriptions for naloxone after a hospitalization, a visit to an
emergency room or a visit to a doctor's office.
Patients were more likely to receive a naloxone prescription if they
had a prior diagnosis of opioid misuse or dependence along with an
overdose compared to individuals who had those diagnoses without an
overdose, the researchers reported. But having a prior diagnosis of
an opioid overdose alone was associated with a decreased likelihood
of receiving naloxone compared with a prior diagnosis of opioid
misuse or dependence without a history of overdose.
In fact, among the 8,895 patients who had a history of opioid
overdose, but no formal diagnosis of opioid misuse or dependence,
only 74, or 0.8 percent, received naloxone. And keep in mind, Pho
said, "there is no greater risk factor for a fatal overdose than a
prior overdose."
[to top of second column] |
Patients were also less likely to receive naloxone if they were
between the ages of 30 and 44 and if they lived in the West or
Midwest.
Pho suspects that much of the problem can be explained by stigma.
"I think there's a reluctance to have an open discussion on this
subject," she said. "Substance use disorder has not been normalized
yet."
"This is a call to arms on the healthcare side," Pho said. "For a
long time healthcare providers have let this responsibility fall to
the community based organizations. They do a great job, but I think
it's time for prescribers to mobilize."
Experts not affiliated with the new research said things have
improved since the time period analyzed in the new report.
"I think there's more naloxone out there now," said Dr. Michael
Fingerhood, an associate professor of medicine and public health at
Johns Hopkins University and chief of the division of addiction
medicine at the Johns Hopkins Bayview Medical Center. "But at the
same time, the potential for overdose is getting worse. We haven't
seen the peak of overdoses yet."
Dr. Michael Lynch agreed that more are getting naloxone
prescriptions now. "If the study period was 15 months later the
findings would be different and the overall percentage would be
higher than 1.5 percent," said Lynch, a toxicologist and emergency
medicine physician and medical director of the Pittsburgh Poison
Center at the University of Pittsburgh Medical Center. "But I
suspect it would still be lower than any of us would want it to be.
I think there are still a lot of missed opportunities to get this
medication in the hands of the people who need it."
Many physicians are still uncomfortable prescribing naloxone, Lynch
said. "And there is a percentage of physicians who hold onto the
false narrative that naloxone will somehow enable or encourage
patients to use opioids," he said.
SOURCE: http://bit.ly/2VHt2ct JAMA Network Open, online May 3, 2019.
[© 2019 Thomson Reuters. All rights
reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |